Short-Course Radiotherapy Followed by Neoadjuvant Bevacizumab, Capecitabine, and Oxaliplatin and Subsequent Radical Treatment in Primary Stage IV Rectal Cancer: Long-Term Results of a Phase II Study
Crossref DOI link: https://doi.org/10.1245/s10434-017-5897-0
Published Online: 2017-05-30
Published Print: 2017-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Bisschop, C.
van Dijk, T. H.
Beukema, J. C.
Jansen, R. L. H.
Gelderblom, H.
de Jong, K. P.
Rutten, H. J. T.
van de Velde, C. J. H.
Wiggers, T.
Havenga, K.
Hospers, G. A. P.
Funding for this research was provided by:
Sanofi-Aventis Netherlands BV
License valid from 2017-05-30